Rafferty Asset Management
PTGX icon

Rafferty Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Rafferty Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.2M Sell
26,099
-20,653
-44% -$2.16M 0.01% 523
2026
Q1 		$4.93M Sell
46,752
-16,909
-27% -$1.5M 0.02% 360
2025
Q4 		$5.56M Sell
63,661
-11,166
-15% -$914K 0.02% 405
2025
Q3 		$4.97M Sell
74,827
-5,716
-7% -$325K 0.02% 428
2025
Q2 		$4.45M Buy
80,543
+36,286
+82% +$1.74M 0.01% 420
2025
Q1 		$2.14M Sell
44,257
-51,210
-54% -$2.15M 0.01% 559
2024
Q4 		$3.69M Buy
95,467
+5,591
+6% +$244K 0.01% 474
2024
Q3 		$4.04M Buy
89,876
+14,606
+19% +$590K 0.01% 463
2024
Q2 		$2.61M Sell
75,270
-163,938
-69% -$4.8M 0.01% 572
2024
Q1 		$6.92M Buy
239,208
+71,413
+43% +$1.94M 0.03% 379
2023
Q4 		$3.85M Sell
167,795
-182,486
-52% -$3.19M 0.02% 504
2023
Q3 		$5.84M Buy
350,281
+64,822
+23% +$1.26M 0.03% 358
2023
Q2 		$7.88M Buy
285,459
+132,072
+86% +$3.31M 0.04% 287
2023
Q1 		$3.53M Sell
153,387
-141,961
-48% -$2.38M 0.02% 472
2022
Q4 		$3.22M Sell
295,348
-51,587
-15% -$435K 0.03% 468
2022
Q3 		$2.92M Buy
346,935
+32,703
+10% +$309K 0.03% 422
2022
Q2 		$2.49M Buy
314,232
+106,138
+51% +$1.28M 0.02% 425
2022
Q1 		$4.93M Buy
208,094
+42,322
+26% +$1.19M 0.03% 398
2021
Q4 		$5.67M Buy
165,772
+96,642
+140% +$3.05M 0.03% 334
2021
Q3 		$1.23M Buy
69,130
+29,938
+76% +$1.28M 0.01% 759
2021
Q2 		$1.76M Sell
39,192
-36,784
-48% -$1.21M 0.01% 724
2021
Q1 		$1.97M Buy
75,976
+62,102
+448% +$1.57M 0.01% 633
2020
Q4 		$280K Sell
13,874
-14,126
-50% -$304K ﹤0.01% 844
2020
Q3 		$547K Buy
+28,000
New +$525K 0.01% 674

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Rafferty Asset Management's PTGX Position: Q2 2026 in Review

Rafferty Asset Management reduced its Protagonist Therapeutics (PTGX) stake by 44% in Q2 2026, selling an estimated $2.16M and leaving 26,099 shares worth $3.2M. The position accounts for 0.01% of the portfolio, ranked #523.

Rafferty Asset Management first reported a position in PTGX in Q3 2020 and has held it in 24 quarters since. The position peaked at $7.88M in Q2 2023. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Rafferty Asset Management held 26,099 shares of Protagonist Therapeutics worth $3.2M as of Q2 2026.
  • Rafferty Asset Management sold 20,653 Protagonist Therapeutics shares in Q2 2026, an estimated $2.16M.
  • Protagonist Therapeutics made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #523 holding.
  • Rafferty Asset Management first reported a position in Protagonist Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Rafferty Asset Management's Protagonist Therapeutics position peaked at $7.88M in Q2 2023.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.